[ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_3393", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_3393" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB00669" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"Sumatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( )] 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( )] 5.2 History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke ee [s Warnings and Precautions ( )] 5.4 Peripheral vascular disease [see Warnings and Precautions ( )] 5.5 Ischemic bowel disease [see Warnings and Precautions ( )] 5.5 Uncontrolled hypertension [see Warnings and Precautions ( )] 5.8 Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT ) agonist 1 [see Drug Interactions ( , )] 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions ( ) and Clinical Pharmacology ( )] 7.2 12.3 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( )] 5.9 Severe hepatic impairment [see Use in Specific Populations ( ) and Clinical Pharmacology ( )] 8.6 12.3 History of coronary artery disease or coronary artery vasospasm ( ) 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( ) 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( ) 4 Peripheral vascular disease ( ) 4 Ischemic bowel disease ( ) Uncontrolled hypertension ( ) 4 4 Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan) or of an ergotamine-containing medication. ( ) 1 4 Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. ( ) 4 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen). ( ) 4 Severe hepatic impairment. ( ) 4\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB00669", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] }, { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#provenance", "@graph": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] }, { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "ZAh6oE0xACbDNCRg2RfWCvcnyRv+XJ9vzKh/Z8eznwTvZCjS7JXJFpAEP8A7ODePRriXLqV/Zc6upMDwsM7tzbxbRvgW27IYpx3wVCiFAGnHpDPclL+rLI7CV86NUegqbA1UQUlQ0kyir50Al2MdibYTLgPbalvzxw4fcFWdnYs=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA" } ] }, { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T13:06:35.109+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] }, { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#Head", "@graph": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RA93ZmHyKvitDBmh1_TIlmcydqIfFHw1358_H0u8thRGA#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] } ]